Edition:
United Kingdom

Soligenix Inc (SNGX.OQ)

SNGX.OQ on NASDAQ Stock Exchange Capital Market

1.75USD
7:28pm BST
Change (% chg)

$-0.05 (-2.78%)
Prev Close
$1.80
Open
$1.79
Day's High
$1.79
Day's Low
$1.75
Volume
1,355
Avg. Vol
25,744
52-wk High
$4.40
52-wk Low
$1.61

Latest Key Developments (Source: Significant Developments)

Soligenix Identifies Biomarkers For Ricin Toxin Vaccine Testing Under FDA Animal Rule
Thursday, 21 Dec 2017 

Dec 21 (Reuters) - Soligenix Inc ::SOLIGENIX IDENTIFIES BIOMARKERS FOR RICIN TOXIN VACCINE TESTING UNDER THE FDA ANIMAL RULE.SOLIGENIX INC - BIOMARKERS FOR RICIN TOXIN VACCINE TESTING BEEN SUCCESSFULLY IDENTIFIED, FACILITATING POTENTIAL APPROVAL UNDER FDA "ANIMAL RULE".SOLIGENIX INC - FURTHER EFFICACY STUDIES IN NHPS EVALUATING POTENTIAL DOSING REGIMENS ARE ANTICIPATED IN 2018.SOLIGENIX - RIVAX DEMONSTRATED REDUCED NUMBER OF VACCINATIONS MAY BE REQUIRED TO ESTABLISH PROTECTION, POTENTIALLY UTILIZING ONLY 2 DOSES INSTEAD OF 3.  Full Article

‍Knoll Capital Management LP​ reports a 9.9 pct passive stake in Soligenix as of Nov 2
Monday, 13 Nov 2017 

Nov 13 (Reuters) - Soligenix Inc :‍Knoll Capital Management LP​ reports a 9.9 percent passive stake in Soligenix Inc as of Nov 2 - SEC Filing.  Full Article

‍ACT Capital Management reports 9.9 pct passive stake in Soligenix - SEC filing​
Tuesday, 7 Nov 2017 

Nov 7 (Reuters) - ‍ACT Capital Management LLLP::‍act Capital Management LLLP reports 9.9 percent passive stake in Soligenix Inc as of November 2, 2017 - SEC filing​.  Full Article

Soligenix reports Q3 loss per share $0.17
Monday, 6 Nov 2017 

Nov 6 (Reuters) - Soligenix Inc :Soligenix announces recent accomplishments and third quarter 2017 financial results.Q3 loss per share $0.17.Q3 revenue $1.82 million versus $2.96 million.Q3 earnings per share view $-0.32 -- Thomson Reuters I/B/E/S.  Full Article

Soligenix Q2 EPS $0.00
Thursday, 11 Aug 2016 

Soligenix Inc : Q2 revenue $3.2 million versus $1.1 million . Soligenix announces recent accomplishments and second quarter 2016 financial results highlighted by revenues of $3.2 million .Q2 earnings per share $0.00.  Full Article

Soligenix announces presentation of phase 2 oral mucositis clinical trial results
Monday, 6 Jun 2016 

Soligenix Inc :Soligenix announces presentation of phase 2 oral mucositis clinical trial results at the 2016 multinational association for supportive care in cancer conference.  Full Article

FDA grants Soligenix "fast track" designation for SGX943
Tuesday, 31 May 2016 

Soligenix Inc :FDA grants Soligenix "fast track" designation for SGX943 for the treatment of melioidosis.  Full Article

Soligenix Q1 loss per share $0.04
Thursday, 12 May 2016 

Soligenix Inc : Soligenix announces recent accomplishments and first quarter 2016 financial results . Q1 revenue $2.6 million versus $800,000 .Q1 loss per share $0.04.  Full Article

BRIEF-Soligenix Receives Orphan Drug Designation From The European Commission For Rivax For Prevention Of Ricin Poisoning

* SOLIGENIX RECEIVES ORPHAN DRUG DESIGNATION FROM THE EUROPEAN COMMISSION FOR RIVAX® FOR PREVENTION OF RICIN POISONING Source text for Eikon: Further company coverage: